alexis ohanian glp-1 Serena Williams says weight loss drug made her healthier than during tennis career Serena Williams is returning to

Weight loss goals are now disease-driven, not cosmetic 5% minimum meaningful benefit 10% required for most metabolic conditions 15% often needed for OSA, HFpEF, MASH, and severe obesity Medication choice is guided by comorbidities GLP-1 receptor agonists and dual GIP/GLP-1 agents are prioritized in patients with: Prediabetes & type 2 diabetes ASCVD Heart failure with preserved EF Metabolic liver disease Obstructive sleep apnea Cardiovascular outcomes now matter Semaglutide 2.4 mg demonstrated a significant reduction in major cardiovascular events even in people without diabetes

Alabamas attorney general recently filed a lawsuit against a medical spa alleging that it administered unapproved versions of GLP-1 weight loss drugs to patients without informing them that the formulations were not authorized by the FDA

Methods Tests included several chromatography methods coupled with ultraviolet and mass spectrometry detectors, inductively coupled plasma optical emission spectroscopy, inductively coupled plasma mass spectrometry, nuclear magnetic resonance, dissolution analyses, in silico peptide/major histocompatibility complex II-binding prediction, and fibrillation assays

Easy application and effective support for your daily goals.

The Tirzepatide Oral Protocol from PlexusDx is a compounded GIP/GLP-1 dual agonist prescribed by licensed providers

Author of The Perimenopause Plan Faye James explains why microdosing a GLP-1 in perimenopause is not recommended.